Somewhat Favorable News Coverage Somewhat Unlikely to Impact NewLink Genetics Corporation (NLNK) Stock Price
News coverage about NewLink Genetics Corporation (NASDAQ:NLNK) has trended somewhat positive on Sunday, according to Accern Sentiment. The research firm identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. NewLink Genetics Corporation earned a news sentiment score of 0.11 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.9795435568726 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
- NewLink Genetics Corporation (NLNK) & The Competition Financial Comparison (americanbankingnews.com)
- Technical gives deep insight into NewLink Genetics Corporation (NLNK) – Wall Street Morning (wallstreetmorning.com)
- Notable Investor’s Alert: QIAGEN NV, (NASDAQ: QGEN), NewLink Genetics Corporation, (NASDAQ: NLNK), United … – Stocks In The News (press release) (tradingnewsnow.com)
- NewLink Genetics Appoints Eugene Kennedy, MD as Chief Medical Officer – GlobeNewswire (press release) (globenewswire.com)
- NewLink Genetics Appoints Eugene Kennedy, M.D. as Chief Medical Officer (finance.yahoo.com)
A number of equities research analysts have weighed in on NLNK shares. Robert W. Baird upgraded shares of NewLink Genetics Corporation from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $8.00 to $22.00 in a report on Friday, September 8th. ValuEngine downgraded shares of NewLink Genetics Corporation from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Stifel Nicolaus upped their target price on shares of NewLink Genetics Corporation from $14.00 to $29.00 and gave the stock a “buy” rating in a research note on Monday, September 11th. Bank of America Corporation began coverage on shares of NewLink Genetics Corporation in a research note on Friday, October 13th. They issued a “buy” rating and a $22.00 target price on the stock. Finally, Cantor Fitzgerald set a $26.00 target price on shares of NewLink Genetics Corporation and gave the stock a “buy” rating in a research note on Friday, July 28th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. NewLink Genetics Corporation currently has an average rating of “Buy” and an average target price of $23.43.
Shares of NewLink Genetics Corporation (NASDAQ:NLNK) opened at $9.61 on Friday. NewLink Genetics Corporation has a 52 week low of $5.90 and a 52 week high of $25.17.
In related news, major shareholder Stine Seed Farm, Inc. bought 780,487 shares of the business’s stock in a transaction that occurred on Friday, October 6th. The stock was bought at an average cost of $10.25 per share, with a total value of $7,999,991.75. Following the completion of the purchase, the insider now owns 7,857,732 shares of the company’s stock, valued at approximately $80,541,753. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 13.70% of the company’s stock.
About NewLink Genetics Corporation
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.